Page last updated: 2024-10-19

niacinamide and Ascites

niacinamide has been researched along with Ascites in 26 studies

nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.

Ascites: Accumulation or retention of free fluid within the peritoneal cavity.

Research Excerpts

ExcerptRelevanceReference
"This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial."9.19Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014)
"The outcomes of sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC) and impaired liver function remain unresolved."7.79Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. ( Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM, 2013)
"Sorafenib was given at a dose of 400 mg/bid (interrupted only around TACE)."6.79TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. ( Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H, 2014)
"This report describes a 6-year-old boy with disseminated low-grade astrocytoma and ventriculo-peritoneal shunt, who developed recurrent ascites while receiving sorafenib on a clinical trial."5.19Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib. ( Chordas, C; Karajannis, MA; Kieran, MW; Legault, G; Milla, SS; Scott, RM, 2014)
" In addition, increased hepatic microvasculatures compliance-related improved buffering effect of portal vein to acute mannitol infusion was associated with decreased circulating nitric oxide and aldosterone, plasma volume expansion (dye dilution method), splanchnic blood pooling ((99 m) Tc-RBC SPECT/PET/CT scans), peripheral hypotension, portal hypertension and ascites in brivanib and sorafenib-treated NASH-cirrhotic rats."3.80Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat. ( Hsieh, YC; Huang, YT; Lee, FY; Lee, KC; Lee, PC; Lee, WP; Lin, HC; Liu, RS; Tan, TW; Yang, YY; Yeh, YC, 2014)
"The outcomes of sorafenib therapy in patients with advanced hepatocellular carcinoma (HCC) and impaired liver function remain unresolved."3.79Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma. ( Joo, J; Kim, CM; Kim, H; Kim, HY; Lee, WJ; Park, JW; Woo, SM, 2013)
"Sorafenib was given at a dose of 400 mg/bid (interrupted only around TACE)."2.79TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial. ( Bitzer, M; Blondin, D; Dollinger, M; Erhardt, A; Gog, C; Häussinger, D; Kolligs, F; Lammert, F; Ohmann, C; Schott, E; Schuchmann, M; Walter, C; Wege, H, 2014)

Research

Studies (26)

TimeframeStudies, this research(%)All Research%
pre-199020 (76.92)18.7374
1990's0 (0.00)18.2507
2000's1 (3.85)29.6817
2010's4 (15.38)24.3611
2020's1 (3.85)2.80

Authors

AuthorsStudies
Kilgour, MK1
MacPherson, S1
Zacharias, LG1
Ellis, AE1
Sheldon, RD1
Liu, EY1
Keyes, S1
Pauly, B1
Carleton, G1
Allard, B1
Smazynski, J1
Williams, KS1
Watson, PH1
Stagg, J1
Nelson, BH1
DeBerardinis, RJ1
Jones, RG1
Hamilton, PT1
Lum, JJ1
Kim, HY1
Park, JW1
Joo, J1
Kim, H1
Woo, SM1
Lee, WJ1
Kim, CM1
Yang, YY1
Liu, RS1
Lee, PC1
Yeh, YC1
Huang, YT1
Lee, WP1
Lee, KC1
Hsieh, YC1
Lee, FY1
Tan, TW1
Lin, HC1
Legault, G1
Kieran, MW1
Scott, RM1
Chordas, C1
Milla, SS1
Karajannis, MA1
Erhardt, A1
Kolligs, F1
Dollinger, M1
Schott, E1
Wege, H1
Bitzer, M1
Gog, C1
Lammert, F1
Schuchmann, M1
Walter, C1
Blondin, D1
Ohmann, C1
Häussinger, D1
HOLZER, H5
BOLTZE, HJ1
KROEGER, H1
ROTTHAUWE, HW1
ULRICH, B2
HILZ, H3
OLDEKOP, M2
SCHOLZ, M1
FRIEDRICH, G1
GRISEBACH, H1
HUDACK, ED1
EROS, DE1
BRUMMOND, DO1
FRIEDLAND, IM1
FULLER, L2
DIETRICH, LS3
PRINA, C2
MAGRASSI, B1
ROVETA, G2
AHUJA, JN1
WOODS, M1
BURK, D1
RAIMONDI, L1
KOHEN, E1
SIEBERT, G1
KOHEN, C1
KUN, E1
LANGER, B1
GRUNICKE, H1
ALTENBRUNN, HJ1
STEENBECK, L1
EHRHARDT, E1
SCHMAGLOWSKI, S1
RUETER, J1
WUEPPEN, I1
KLEMPIEN, EJ1
MIELSCH, M1
GRIMBERG, H1
DOLD, U1
REDETZKI, HM1
O'BOURKE, FA1
SCHNEIDER, M1
Kamat, JP1
Devasagayam, TP1
Ofori-Nkansah, N2
von Bruchhausen, F2

Clinical Trials (2)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Phase II Study of Sorafenib in Children and Young Adults With Recurrent or Progressive Low-Grade Astrocytomas[NCT01338857]Phase 212 participants (Actual)Interventional2011-04-30Terminated (stopped due to Sorafenib ineffective for tx of recurrent or progressive PLGA)
Phase II Study Evaluating Transarterial Chemoembolization (TACE) in Combination With Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (HCC)[NCT00618384]Phase 243 participants (Actual)Interventional2008-01-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Objective Response Rates

Determination of tumor response (CR, PR, SD) will be defined based on the comparison of the baseline MRI performed at study entry to the subsequent MRI which demonstrated best response. PR will be defined by a >15% decrease in tumor volume, as measured by 3D volumetric analysis. (NCT01338857)
Timeframe: MRIs performed after every 3rd 28-day cycle and off-study

Interventionparticipants (Number)
Sorafenib (Nexavar)1

Response Rate to Sorafenib

To estimate the objective response rates to sorafenib in children and young adults with low-grade astrocytomas, including optic pathway gliomas. (NCT01338857)
Timeframe: one year

Interventionparticipants (Number)
Sorafenib (Nexavar)1

Trials

2 trials available for niacinamide and Ascites

ArticleYear
Recurrent ascites in a patient with low-grade astrocytoma and ventriculo-peritoneal shunt treated with the multikinase inhibitor sorafenib.
    Journal of pediatric hematology/oncology, 2014, Volume: 36, Issue:8

    Topics: Ascites; Astrocytoma; Brain Neoplasms; Child; Humans; Magnetic Resonance Imaging; Male; Niacinamide;

2014
TACE plus sorafenib for the treatment of hepatocellular carcinoma: results of the multicenter, phase II SOCRATES trial.
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:5

    Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carcinoma, Hepatocellular; Chemoembol

2014

Other Studies

24 other studies available for niacinamide and Ascites

ArticleYear
1-Methylnicotinamide is an immune regulatory metabolite in human ovarian cancer.
    Science advances, 2021, Volume: 7, Issue:4

    Topics: Ascites; Female; Humans; Niacinamide; Ovarian Neoplasms; Tumor Microenvironment

2021
Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
    Journal of gastroenterology and hepatology, 2013, Volume: 28, Issue:11

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Ascites; Carcinoma, Hepatocellular; Female; F

2013
Anti-VEGFR agents ameliorate hepatic venous dysregulation/microcirculatory dysfunction, splanchnic venous pooling and ascites of NASH-cirrhotic rat.
    Liver international : official journal of the International Association for the Study of the Liver, 2014, Volume: 34, Issue:4

    Topics: Alanine; Animals; Ascites; Cytokines; DNA Primers; Fatty Liver; Fibroblast Growth Factors; Microcirc

2014
[On the effect of nicotinic acid amide on the inhibition of glycolysis in ascites tumor cells by ethylene imine compounds].
    Zeitschrift fur Krebsforschung, 1961, Volume: 64

    Topics: Amides; Animals; Antineoplastic Agents; Ascites; Carbohydrate Metabolism; Carbohydrates; Carcinoma,

1961
[On the influence of carcinostatic agents on the DPN metabolism of tumors. I. Incorporation of C-14-ribose and C-14-nicotinamide into the DPN of ascites cells].
    Biochemische Zeitschrift, 1960, Volume: 333

    Topics: Antineoplastic Agents; Ascites; Coenzymes; NAD; Neoplasms; Niacin; Niacinamide; Nicotinic Acids; Rib

1960
Effects of x-ray irradiation in ascites tumor cells: partial restoration of DPN content and DNA synthesis by nicotinamide.
    Biochemical and biophysical research communications, 1961, Dec-20, Volume: 6

    Topics: Animals; Ascites; Coenzymes; DNA; DNA Replication; NAD; Neoplasms, Experimental; Niacin; Niacinamide

1961
[Evaluation of nicotinic acid and nicotinamide for the biosynthesis of DPN in ascites tumor cells].
    Biochimica et biophysica acta, 1961, Aug-19, Volume: 51

    Topics: Ascites; Coenzymes; NAD; Neoplasms; Niacin; Niacinamide; Nicotinic Acids

1961
Studies on Ehrlich ascites cell nuclei. IV. Determination of nicotinamide adenosine dinucleotide pyrophosphorylase activity in nuclei isolated by an improved technique.
    Experimental cell research, 1963, Volume: 29

    Topics: Adenosine; Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; Cell Nucleus; NAD; Niacinamide; Ph

1963
Nicotinic acid and nicotinamide metabolism in ascites cells in vitro.
    The Journal of biological chemistry, 1962, Volume: 237

    Topics: Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; In Vitro Techniques; NAD; Niacin; Niacinamide

1962
[Complexes of 3,4-benzopyrene and various substances in aqueous solution. Action in vitro and in vivo on Ehrlich's ascites cancer cells].
    Bollettino della Societa italiana di biologia sperimentale, 1962, Dec-15, Volume: 38

    Topics: Animals; Ascites; Benzo(a)pyrene; Benzopyrenes; Caffeine; Carcinoma; Carcinoma, Ehrlich Tumor; Hista

1962
Uptake of nicotinic acid-C-14 and nicotinamide-C-14 by ascites cells in vitro.
    The Journal of biological chemistry, 1963, Volume: 238

    Topics: Ascites; In Vitro Techniques; NAD; Neoplasms; Neoplasms, Experimental; Niacin; Niacinamide; Nicotini

1963
FORMATION OF GLYCOLYTIC INHIBITOR FROM 6-AMINONICOTINAMIDE BY ASCITES TUMOR CELLS IN VIVO AND IN VITRO, AND METABOLIC REQUIREMENTS FOR FORMATION OF THIS INHIBITOR.
    Biochemische Zeitschrift, 1963, Volume: 338

    Topics: 6-Aminonicotinamide; Animals; Ascites; Carbohydrate Metabolism; Carcinoma, Ehrlich Tumor; Enzyme Inh

1963
[ACTION OF WATER-SOLUBLE COMPLEXES OF 3,4-BENZOPYRENE ON TUMOR ASCITES FLUIDS. ELECTROPHORETIC STUDIES].
    Bollettino della Societa italiana di biologia sperimentale, 1963, Dec-15, Volume: 39

    Topics: Animals; Ascites; Benzo(a)pyrene; Benzopyrenes; Carbohydrates; Carcinoma, Ehrlich Tumor; Electrophor

1963
METABOLISM OF REDUCED PYRIDINE NUCLEOTIDES IN ASCITES CELL NUCLEI.
    Zeitschrift fur Zellforschung und Mikroskopische Anatomie. Abteilung Histochemie, 1964, Apr-10, Volume: 78

    Topics: Amobarbital; Ascites; Cell Nucleus; Citrates; Fluorescence; Fluorometry; Glucose; Histocytochemistry

1964
NICOTINAMIDE ADENINE DINUCLEOTIDE SYNTHESIS IN ASCITES CELLS IN VITRO.
    The Journal of biological chemistry, 1964, Volume: 239

    Topics: Ascites; Carbon Isotopes; Chromatography; Glucose; Glutamine; In Vitro Techniques; Metabolism; Mice;

1964
THE ROLE OF DPNASE IN THE MECHANISM OF ACTION OF AN ANTITUMOR ALKYLATING AGENT ON EHRLICH ASCITES CELLS.
    Proceedings of the National Academy of Sciences of the United States of America, 1964, Volume: 52

    Topics: Alkylating Agents; Animals; Antineoplastic Agents; Ascites; Carbohydrate Metabolism; Carcinoma; Carc

1964
[INVESTIGATION ON THE DECREASE IN CONCENTRATION OF NAD IN LYMPHOSARCOMA ASCITES CELLS FOLLOWING X-IRRADIATION].
    International journal of radiation biology and related studies in physics, chemistry, and medicine, 1965, Volume: 9

    Topics: Ascites; Chromatography; Lymphoma; Lymphoma, Non-Hodgkin; Metabolism; NAD; Neoplasms; Neoplasms, Exp

1965
STIMULATION OF DPN TURNOVER IN ASCITES TUMOR CELLS BY LOW X-RAY DOSES.
    Life sciences (1962), 1965, Volume: 4

    Topics: Animals; Ascites; Carcinoma; Carcinoma, Ehrlich Tumor; DNA; DNA, Neoplasm; Metabolism; N-Glycosyl Hy

1965
[On the effect of cytostatic compounds and nicotinic acid amide on ascites tumor ribonuclease (n)].
    Biochemische Zeitschrift, 1959, Volume: 331

    Topics: Amides; Animals; Antineoplastic Agents; Ascites; Carcinoma, Ehrlich Tumor; Humans; Neoplasms, Experi

1959
[Influence of nicotinamide on the DPN-content, glycolysis and viability of ascites tumor cells after treatment with carcinostatic ethyleneimine compounds].
    Biochimica et biophysica acta, 1962, Aug-27, Volume: 62

    Topics: Animals; Antineoplastic Agents; Ascites; Aziridines; Coenzymes; Glycolysis; Humans; NAD; Neoplasms,

1962
Influence of nicotic acid and nicotinamide on diphosphopyridine nucleotide (DPN) Synthesis in ascites tumor cells.
    Biochemical pharmacology, 1961, Volume: 8

    Topics: Animals; Ascites; Carcinoma, Ehrlich Tumor; Coenzymes; NAD; Neoplasms; Niacin; Niacinamide; Nicotini

1961
Oxidative damage to mitochondria in normal and cancer tissues, and its modulation.
    Toxicology, 2000, Nov-30, Volume: 155, Issue:1-3

    Topics: Animals; Antioxidants; Ascites; Brain; Caffeine; Gamma Rays; Male; Mitochondria, Liver; Niacinamide;

2000
Metabolic alterations in Yoshida ascites tumour cells caused by 6-aminonicotinamide and prevented by nicotinamide.
    Naunyn-Schmiedeberg's archives of pharmacology, 1972, Volume: 272, Issue:2

    Topics: Amines; Animals; Ascites; Carbon Dioxide; Carbon Isotopes; Fructosephosphates; Gluconates; Glucose;

1972
Some metabolic and morphological alterations in Yoshida ascites tumour cells caused by 6-aminonicotinamide.
    Zeitschrift fur Krebsforschung und klinische Onkologie. Cancer research and clinical oncology, 1972, Volume: 77, Issue:1

    Topics: Animals; Ascites; Cell Nucleus; Endoplasmic Reticulum; Fructosephosphates; Gluconates; Glucose-6-Pho

1972